CYSVIEW KIT

Peak

hexaminolevulinate hydrochloride

NDAINTRAVESICALFOR SOLUTIONPriority Review
Approved
May 2010
Lifecycle
Peak
Competitive Pressure
0/100

Mechanism of Action

precursor, aminolevulinic acid. After bladder instillation, Cysview enters the bladder mucosa and is proposed to enter the intracellular space of mucosal cells where it is used as a precursor in the formation of the photoactive intermediate protoporphyrin IX (PpIX) and other photoactive porphyrins…

Loss of Exclusivity

LOE Date
Jan 4, 2038
144 months away
Patent Expiry
Jan 4, 2038

Patent Records (3)

Patent #ExpiryTypeUse Code
10556010
Dec 19, 2036
U-2250
11311620
Dec 19, 2036
U-2250
11235168
Jan 4, 2038
U-2250
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers